Roflumilast enhances Liraglutide's atrial natriuretic peptide-dependent suppression of adrenal aldosterone secretion.
Background
Primary hyperaldosteronism, characterized by excessive aldosterone production, is a significant cause of hypertension and cardiovascular disease. Current treatments often involve mineralocorticoid receptor antagonists, but direct suppression of aldosterone secretion remains a therapeutic goal. Atrial natriuretic peptide (ANP) is a key hormone that counteracts aldosterone, promoting natriuresis and vasodilation. The GLP-1 receptor (GLP-1R) agonist liraglutide has shown cardiovascular benefits beyond glucose control, including effects on blood pressure. This study investigates how liraglutide influences ANP and aldosterone, and if the PDE4 inhibitor roflumilast can augment these effects, addressing a gap in understanding combination therapies for aldosterone-related cardiovascular conditions.
Study Design
Researchers investigated the effects of liraglutide and roflumilast on ANP and aldosterone secretion using H9c2 cardiomyocytes and H295R human adrenocortical cells. H9c2 cardiomyocytes were treated with liraglutide (concentration not specified) alone or in combination with roflumilast (concentration not specified). The study also employed adenylyl cyclase (AC) inhibition and Epac inhibition with ESI-09 to elucidate underlying mechanisms. Conditioned medium from H9c2 cells treated with liraglutide and roflumilast was then applied to H295R adrenocortical cells to assess aldosterone secretion. ANP receptor blockade was used to confirm ANP's role. Key endpoints included ANP secretion, aldosterone secretion, intracellular cAMP levels, and Epac1/2 and ANP gene/protein expression via qPCR and Western blot.
Results
Liraglutide significantly stimulated ANP secretion from H9c2 cardiomyocytes, an effect that was further potentiated by roflumilast. This ANP secretion was blocked by AC inhibition, indicating a cAMP-dependent mechanism. Furthermore, Epac inhibition with ESI-09 significantly reduced liraglutide-dependent ANP secretion in H9c2 cardiomyocytes, highlighting the role of Epac signaling. Conditioned medium from H9c2 cells treated with liraglutide effectively suppressed aldosterone secretion from H295R adrenocortical cells. This suppressive effect on aldosterone was notably enhanced when roflumilast was co-administered with liraglutide to the H9c2 cells. The ANP receptor blockade completely reversed this suppression of aldosterone, confirming ANP as the primary mediator. Mechanistically, liraglutide increased cAMP levels in H9c2 cells, an effect potentiated by roflumilast. > Liraglutide also increased the expression of Epac1 and Epac2 in H9c2 cells, and this increase was further potentiated by roflumilast, alongside increases in ANP mRNA and protein expression. These findings collectively demonstrate a synergistic action between liraglutide and roflumilast in regulating the ANP-aldosterone axis.
Key Findings
- Liraglutide stimulated ANP secretion from H9c2 cardiomyocytes.
- Roflumilast potentiated liraglutide's ANP secretion in H9c2 cells.
- Liraglutide-treated H9c2 medium suppressed aldosterone secretion from H295R cells.
- Roflumilast enhanced liraglutide's suppression of aldosterone secretion.
- Liraglutide increased cAMP and Epac1/2 expression, potentiated by roflumilast.
Why It Matters
This research suggests a novel therapeutic strategy for hypertension and hyperaldosteronism by combining a GLP-1R agonist with a PDE4 inhibitor. Combining liraglutide with roflumilast could offer enhanced cardiovascular protection by more effectively suppressing aldosterone, a key driver of cardiac and renal damage. For peptide users and clinicians, this opens the door to exploring GLP-1 agonists in conjunction with PDE4 modulators for conditions beyond their primary indications, potentially improving outcomes in patients with elevated aldosterone. While currently an in vitro finding, it provides a mechanistic basis for future in vivo and clinical trials, potentially leading to new combination protocols for managing blood pressure and cardiovascular risk.